Amgen

Categories: Companies traded on NASDAQ | Companies traded on the Hong Kong Stock Exchange | Medical corporation stubs | Companies based in California | Biotechnology companies | Pharmaceutical companies | Portmanteaus

Amgen Inc. (NASDAQ: AMGN) (HKSE: 4332) is an international biotechnology company headquartered in Thousand Oaks, California. Amgen is the largest independent biotech firm, with approx. 15,000 staff members in 2005. Its products include EPOGEN, ARANESP, ENBREL, Kineret, Neulasta, NEUPOGEN, and Sensipar. EPOGEN and NEUPOGEN (the company's first products to hit the market) were the two most successful biopharmaceutical products at the time of their respective releases.

BusinessWeek (as cited in "References") ranked Amgen fourth on the S&P 500 for being the most "future-oriented" of those five hundred corporations.^[1] BusinessWeek ostensibly calculated the ratio of research and development spending, combined with capital spending, to total outlays; Amgen had the fourth highest ratio, at 506:1000. Amgen is the largest employer in Thousand Oaks and second only to the United States Navy in terms of number of people employed in Ventura County.

Amgen is a member of the Pensylvania Bio commerce organization, though it appears not to maintain a facility in the Pennsylvania (United States).^[2]

Contents 1 History 2 References 3 See also 4 Company Profiles

History

The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics.

References

1. ^  Coy, Peter: “The Search for Tomorrow”, BusinessWeek, 11 October 2004. access to article requires free registration on site
2. ^  “Pennsylvania Bio - Member Listings.” Pennsylvania Bio web site. Accessed on October 8, 2005.

See also

• Kirin-Amgen v Hoechst Marion Roussel, a UK patent case decided by the House of Lords.

Company Profiles

• Amgen Inc. Company Profile at Yahoo!

Ever wanted to know the meaning of life?

Powered by Hondunet